About this journal
Aims and scope
Expert Opinion on Pharmacotherapy [ISSN 1465-6566]; [e-ISSN 1744-7666] is a MEDLINE-indexed, international subscription-based journal publishing rigorously peer-reviewed review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development.
Expert Opinion on Pharmacotherapy addresses the needs of research and development, regulatory and marketing decision makers in the pharmaceutical industry and decision makers in healthcare provision.
The Editors welcome:
- Reviews covering new drugs/drug classes for specific diseases, from development Phase III to those that have been available to pharmacopoeia for up to 5 years, and their potential impact on future treatment strategies.
- Drug Evaluations reviewing the clinical and pharmacological data on a particular drug.
- Original Research papers reporting the results of clinical investigations on agents that are in Phase III and IV clinical trials and pharmacologically based studies with a strong link to clinical practice.
Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees.
Please note that the journal does not publish case reports, case series, or animal studies.
Reach an international clinical and medical audience alongside other key option leaders in your field by publishing with Expert Opinion on Pharmacotherapy, part of the Expert Collection brand.
For any pre-submission enquiries, please contact the Commissioning Editor.
Journal metrics
Usage
- 427K annual downloads/views
Citation metrics
- 2.5 (2023) Impact Factor
- 3.3 (2023) 5 year IF
- 5.6 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.747 (2023) SNIP
- 0.687 (2023) SJR
Speed/acceptance
- 25 days avg. from submission to first decision
- 38 days avg. from submission to first post-review decision
- 7 days avg. from acceptance to online publication
- 59% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
EDITORIAL ADVISORY BOARD
Prof. Wilbert Aronow, Westchester Medical Center, Valhalla, NY, USA
Prof. Maciej Banach, Polish Mothers Memorial Hospital, Lodz, Poland
Dr. Francesco Brigo, Hospital of Merano, Merano-Meran, Italy
Dr. Sara Bringhen, A.O.U. City of Health and Sciences, Turin, Italy
Dr. Leslie Citrome, New York Medical College, Valhalla, NY, USA
Dr. Thomas Ciulla, Midwest Eye Institute, Carmel, IN, USA
Dr. Constantin A Dasanu, University of California San Diego, San Diego, CA, USA
Prof. Stephen N Davis, University of Maryland Medical Center, Baltimore, MD, USA
Prof. Erik de Clercq, Retired, Belgium
Dr. Guillermo Di Girolamo, University of Buenos Aires, Buenos Aires, Argentina
Dr. Sheila A Doggrell, Queensland University of Technology, Brisbane, Australia
Dr. Jaime Esteban, Jiménez Díaz Foundation University Hospital, Madrid, Spain
Prof. Steven Feldman, Wake Forest School of Medicine, Winston-Salem, NC, USA
Prof. Simone Ferrero, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
Prof. Jakub Fichna, University of Lodz, Lodz, Poland
Dr. Robert L Findling, Johns Hopkins University, Baltimore, MD, USA
Prof. Kostas N Fountoulakis, Aristotle University of Thessaloniki, Thessaloniki, Greece
Dr. Daniela Galimberti, University of Milan, Milan, Italy
Dr. Daniele R Giacobbe, University of Genoa, Genoa, Italy
Paul Greenberg, Analysis Group, Inc, Boston, MA, USA
Prof. George Grossberg, St Louis University School of Medicine, St. Louis, MO, USA
Prof. Paul Gurbel, Inova Center for Thrombosis Research and Drug Development, Falls Church, MD, USA
Prof. Nicola Hanania, Baylor College of Medicine, Houston, TX, USA
Prof. Michael G Irwin, University of Hong Kong, Pok Fu Lam, Hong Kong SAR
Prof. Siegfried Kasper, University of Vienna, Vienna, Austria
Prof. Catherine Kelly, University College Dublin, Dublin, Ireland
Prof. Jay Khastgir, Swansea University, Swansea, UK
Prof. Anastasios Konstas, Aristotle University of Thessaloniki, Thessaloniki, Greece
Prof. Sandro La Vignera, University of Catania, Catania, Italy
Dr. Herbert A Kirst, Consultant, Indianapolis, IN, USA
Prof. Ken Lee, Monash University, Subang Jaya, Malaysia
Prof. Gregory Y Lip, University of Liverpool, Liverpool, UK
Dr. Shari Lipner, Weill Cornell Medical College, New York, NY, USA
Prof. Donatella Marazziti, University of Pisa, Pisa, Italy
Prof. Hartmut Lode, Charité – Universitätsmedizin Berlin, Berlin, Germany
Prof. Sharon Marsh, University of Alberta, Edmonton, AB, Canada
Prof. Paolo Martelletti, Sapienza University of Rome, Rome, Italy
Prof. Maria G Matera, University of Campania Luigi Vanvitelli, Campania, Italy
Prof. Dimitri Mikhailidis, University College London, London, UK
Prof. Filippo Montemurro, Istituto di Candiolo, Candiolo, Italy
Dr. Marco Mula, St George's University, London, UK
Prof. Thomas Muller, St Joseph Hospital, Berlin, Germany
Prof. Benoit Mulsant, University of Toronto, Toronto, ON, Canada
Dr. Eduardo Mysler, Organización Médica de Investigación, Buenos Aires, Buenos Aires, Argentina
Dr. Francesco Panza, National Institute of Gastroenterology "Saverio de Bellis", Research Hospital, Bari, Italy
Prof. Athanasios Papatsoris, University of Athens, Athens, Greece
Prof. Petros Perimenis, University Hospital of Patras, Patras, Greece
Prof. Gerald E Piérard, University Hospital of Liège, Liège, Belgium
Prof. Tadusz Robak, Medical University of Lodz, Lodz, Poland
Dr. Massimiliano Ruscica, University of Milan, Milan, Italy
Dr. Emilio Sacco, Catholic University of the Sacred Heart, Milan, Italy
Prof. Ernst R Schwarz, Cedars Sinai Medical Center, Culver City, CA, USA
Dr. Nicholas Short, University of Texas MD Anderson Cancer Center, Houston, TX, USA
Prof. Dave Singh, Medicines Evaluation Unit, Manchester, UK
Prof. Guru Sonpavde, Harvard University, Cambridge, MA, USA
Prof. Carol Stanciu, Institute of Gastroenterology and Hepatology, Iasi, Romania
Dr. Jeffrey Strawn, University of Cincinnati, Cincinnati, OH, USA
Prof. Yoshiya Tanaka, University of Occupational & Environmental Health, Kitakyushu, Japan
Prof. Theoharis Theoharides, Tufts University, Medford, MA, USA
Prof. Brian Tomlinson, The Chinese University of Hong Kong, Hong Kong SAR
Prof. Giuseppe Tonini, University Campus Bio-Medico, Rome, Italy
Prof. Antoni Torres, Clinical and Provincial Hospital of Barcelona, Barcelona, Spain
Prof. Laszlo Vecsei, University of Szeged, Szeged, Hungary
Prof. Uwe Wollina, Städtisches Klinikum Dresden, Dresden, Germany
Prof. Joyce H You, The Chinese University of Hong Kong, Hong Kong SAR
Abstracting and indexing
Expert Opinion on Pharmacotherapy
is included in the following abstracting and indexing services:Chemical Abstracts (CODEN: EOPHF7); Current Contents®/Clinical Medicine; EMBASE/Excerpta Medica; Index to Scientific Reviews; Index Medicus/Medline; ISI Alerting Services™; Science Citation Index Expanded.
Open access
Expert Opinion on Pharmacotherapy is a hybrid open access journal that is part of our Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
If you choose to publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis.
Use our APC finder to calculate your article publishing charge
News, offers and calls for papers
News and offers
18 issues per year
Associated with:
- Expert Review of Pharmacoeconomics & Outcomes Research (2001 - current)
- Expert Opinion on Biological Therapy (2001 - current)
- Expert Opinion on Drug Safety (2002 - current)
- Expert Opinion on Emerging Drugs (2001 - current)
Advertising information
Would you like to advertise in Expert Opinion on Pharmacotherapy?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Expert Opinion on Pharmacotherapy.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors, make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors